A Randomized, Phase II, Multicenter, Open Label, Study Evaluating Sirolimus and Prednisone in Patients With Refined Minnesota Standard Risk, Ann Arbor 1/2 Confirmed Acute Graft-Versus-Host Disease (BMT CTN 1501)
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 22 Mar 2018
At a glance
- Drugs Sirolimus (Primary) ; Prednisone
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- 19 Mar 2018 Planned End Date changed from 1 Oct 2020 to 1 Feb 2020.
- 19 Mar 2018 Planned primary completion date changed from 1 Oct 2019 to 1 Feb 2019.
- 19 Mar 2018 Status changed from recruiting to active, no longer recruiting.